{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:50:19Z","timestamp":1791478219296,"version":"4.3.4"},"reference-count":25,"publisher":"Massachusetts Medical Society","issue":"22","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"DOI":"10.13039\/100013986","name":"UK Foreign, Commonwealth & Development Office","doi-asserted-by":"publisher","award":["PATH Product Development Partnership 2017 to 2021:"],"award-info":[{"award-number":["PATH Product Development Partnership 2017 to 2021:"]}],"id":[{"id":"10.13039\/100013986","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2021,6,3]]},"DOI":"10.1056\/nejmoa2013615","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T17:08:00Z","timestamp":1622653680000},"page":"2115-2123","source":"Crossref","is-referenced-by-count":35,"title":["Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian Toddlers"],"prefix":"10.1056","volume":"384","author":[{"given":"Milagritos D.","family":"Tapia","sequence":"first","affiliation":[{"name":"From Centre pour le D\u00e9veloppement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samba O.","family":"Sow","sequence":"additional","affiliation":[{"name":"From Centre pour le D\u00e9veloppement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdi","family":"Naficy","sequence":"additional","affiliation":[{"name":"From Centre pour le D\u00e9veloppement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatoumata","family":"Diallo","sequence":"additional","affiliation":[{"name":"From Centre pour le D\u00e9veloppement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadima C.","family":"Haidara","sequence":"additional","affiliation":[{"name":"From Centre pour le D\u00e9veloppement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9972-9755","authenticated-orcid":false,"given":"Amol","family":"Chaudhari","sequence":"additional","affiliation":[{"name":"From Centre pour le D\u00e9veloppement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Martellet","sequence":"additional","affiliation":[{"name":"From Centre pour le D\u00e9veloppement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awa","family":"Traore","sequence":"additional","affiliation":[{"name":"From Centre pour le D\u00e9veloppement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Townsend-Payne","sequence":"additional","affiliation":[{"name":"From Centre pour le D\u00e9veloppement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[{"name":"From Centre pour le D\u00e9veloppement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Hosken","sequence":"additional","affiliation":[{"name":"From Centre pour le D\u00e9veloppement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Smolenov","sequence":"additional","affiliation":[{"name":"From Centre pour le D\u00e9veloppement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sambhaji S.","family":"Pisal","sequence":"additional","affiliation":[{"name":"From Centre pour le D\u00e9veloppement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Marc","family":"LaForce","sequence":"additional","affiliation":[{"name":"From Centre pour le D\u00e9veloppement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev M.","family":"Dhere","sequence":"additional","affiliation":[{"name":"From Centre pour le D\u00e9veloppement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhananjay","family":"Kapse","sequence":"additional","affiliation":[{"name":"From Centre pour le D\u00e9veloppement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiao","family":"Tang","sequence":"additional","affiliation":[{"name":"From Centre pour le D\u00e9veloppement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Alderson","sequence":"additional","affiliation":[{"name":"From Centre pour le D\u00e9veloppement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad S.","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"From Centre pour le D\u00e9veloppement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","unstructured":"Meningococcal meningitis. World Health Organization 2018 (https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/meningococcal-meningitis)."},{"key":"e_1_3_5_3_2","first-page":"129","article-title":"Meningococcal disease in countries of the African meningitis belt, 2012 \u2014 emerging needs and future perspectives.","volume":"88","year":"2013","unstructured":"Meningococcal disease in countries of the African meningitis belt, 2012 \u2014 emerging needs and future perspectives. Wkly Epidemiol Rec 2013;88:129-136.23544241","journal-title":"Wkly Epidemiol Rec"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.04.063"},{"key":"e_1_3_5_5_2","unstructured":"Meningococcal meningitis weekly reports: 2013\u20132017. World Health Organization (http:\/\/www.who.int\/csr\/disease\/meningococcal\/epidemiological\/en\/index.html)."},{"key":"e_1_3_5_6_2","first-page":"145","article-title":"Epidemic meningitis control in countries of the African meningitis belt, 2016.","volume":"92","year":"2017","unstructured":"Epidemic meningitis control in countries of the African meningitis belt, 2016. Wkly Epidemiol Rec 2017;92:145-154.28361528","journal-title":"Wkly Epidemiol Rec"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ500"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1412022"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30301-8"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ597"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6649a3"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3247-x"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2204.150653"},{"key":"e_1_3_5_14_2","first-page":"1825","article-title":"Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix): a review of its immunogenicity, safety, co-administration, and antibody persistence.","volume":"12","author":"Assaf-Casals A","year":"2016","unstructured":"Assaf-Casals A, Dbaibo G. Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix): a review of its immunogenicity, safety, co-administration, and antibody persistence. Hum Vaccin Immunother 2016;12:1825-1837.26900984","journal-title":"Hum Vaccin Immunother"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30400-6"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-9202-7_12"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780040211"},{"key":"e_1_3_5_18_2","unstructured":"Menactra. Swiftwater PA: Sanofi Pasteur 2018 (https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM131170.pdf) (package insert)."},{"key":"e_1_3_5_19_2","unstructured":"Nimenrix summary of product characteristics. European Medicines Agency 2017 (http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-Product_Information\/human\/002226\/WC500127663.pdf)."},{"key":"e_1_3_5_20_2","unstructured":"MENVEO. Research Triangle Park NC: GlaxoSmithKline 2020 (https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM201349.pdf) (package insert)."},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.04.036"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/11204790-000000000-00000"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.09.092"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188595"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002495"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X19859899"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2013615","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T18:27:28Z","timestamp":1749666448000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2013615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":25,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2021,6,3]]}},"alternative-id":["10.1056\/NEJMoa2013615"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2013615","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,3]]}}}